Jose Luis Subiza

médico, inmunólogo, profesor, empresario

[Jose Luis Subiza @JoseSubiza]

@SEinmunologia @Forbes_es Enhorabuena Silvia! Muy merecido!!

[Salva Iborra @salva_iborra]

Preventing type 2 inflammation and allergic asthma with the mucosal polybacterial vaccine MV130 from @inmunotek.

[Salva Iborra @salva_iborra]

Nueva publicación @LunaMinute @arlosdel acerca de cómo funcionan las #vacunas de mucosa basadas en inmunidad entrenada (TIbVs) en la prevención de infecciones respiratorias, entre ellas MV130, desarrollada por @Inmunotek
📄 https://t.co/SABRrf3YIb
#AMR #InmunidadEntrenada

[Jose Luis Subiza @JoseSubiza]

Immunity: Descubren cómo el intestino puede influir en el desarrollo de enfermedades inflamatorias o cardiovasculares https://t.co/RnItmq8PxJ

[Salva Iborra @salva_iborra]

1/3 📢 New research on MV130, a mucosal polybacterial vaccine developed by @inmunotek , shows potential in attenuating experimental ulcerative colitis. It reduces inflammation, protects the gut barrier, and promotes immune tolerance: https://t.co/UeMmoI3HwN

[Jose Luis Subiza @JoseSubiza]

https://t.co/Xq5WDadkG7

[Jose Luis Subiza @JoseSubiza]

UTIs make life miserable — scientists are finding new ways to tackle them https://t.co/loTXr4ckg7

[Jose Luis Subiza @JoseSubiza]

@SilviaSchzRamon @SEinmunologia Enhorabuena Silvia! Vas a poner muy arriba a la SEI y el listón muy alto para los siguientes. Que tengas mucha suerte con el reto! Un fuerte abrazo!!

[Silvia Sánchez-Ramón @SilviaSchzRamon]

Biomedicines | Free Full-Text | Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression https://t.co/hRtJayXP92

[CArlosdelFresnoSánchez @arlosdel]

Terrific panel of speakers for the WISH-A meeting in Alicante. Really thankful to have been invited to give a talk. Thank you @inmunotek. Feeling strong from @IdipazScience !!

[Jorge Domínguez-Andrés @dominjor]

Voilà! Our new study is out in @FrontImmunol. Thank you for the nice collaboration. Now on to the next one! @ozlemthefrogge @mariacegove 🧫⬇️

https://t.co/S1Cr0QTW17

[Jose Luis Subiza @JoseSubiza]

Do bacterial vaccines/adjuvants prevent wheezing episodes in children? https://t.co/vBGsU7kU70

[Christine Stabell Benn @StabellBenn]

Vaccine curious? Hear Prof. Netea tells how he discovered that vaccines can affect the innate immune system (previously believed to be without a memory) in profound ways - and how that may affect the use of vaccines in the future. https://t.co/VcvmJyZ92N
https://t.co/2AmrGIWy8e

[Allergy EAACI @AllergyEaaci]

Nieto, et al., First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual #immunotherapy.

Read the article here👉 https://t.co/mjsICBPgPw

See more papers👉 https://t.co/oHigjNq0sS

#Allergy_journal

[Jose Luis Subiza @JoseSubiza]

First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy https://t.co/Rw1ChCc0y5

[Daniel Jimenez Muñoz @DJimenezMunoz]

▷ Tengo algo importante que decirte: estoy ahora mismo en la mesa redonda que organiza @Cepyme_ bajo el título: Claves del Presente y Futuro de la Digitalización de la PYME Española?

¿Dónde? En el @cbamadrid con @carmeartigas y
@josezimmer

[Frontiers in Allergy @FrontAllergy]

📣Calling early career researchers!
We invite researchers within 15 years of completing their Ph.D., M.D., or equivalent terminal degrees to submit to:

Rising Stars in in Allergen Immunotherapy Research: 2022
👉https://t.co/56Lpd6JzpR

#callforpapers #openaccess
@JoseSubiza

[Jose Luis Subiza @JoseSubiza]

A New Strategy to Prevent “Deja vUTI” | NEJM Evidence https://t.co/gVkLx9ibWW

[Jose Luis Subiza @JoseSubiza]

Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections | NEJM Evidence https://t.co/AeQ9jcKDCv

[Jose Luis Subiza @JoseSubiza]

Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections https://t.co/8foMdhSJ2q